A O
new O
brominated B
C I
( I
17 I
) I
acetylenic I
acid I
( O
1 O
) O
designated O
as O
bromotheoynic B
acid I
has O
been O
isolated O
from O
the O
marine O
sponge O
Theonella O
swinhoei O
, O
collected O
off O
the O
coast O
of O
Tanegashima O
, O
Kagoshima O
Prefecture O
, O
Japan O
. O

Cyclo B
- I
( I
His I
, I
Leu I
) I
: O
a O
new O
microbial O
diketopiperazine B
from O
a O
terrestrial O
Bacillus O
subtilis O
strain O
B38 O
. O

Trp I
, I
Tyr I
) I
( O
5 O
) O
and O
macrolactin B
A I
( O
6 O
) O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
time O
that O
cyclo B
- I
( I
His I
, I
Leu I
) I
has O
been O
isolated O
from O
natural O
products O
. O

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

2 B
- I
Hydroxy I
- I
4 I
- I
methoxybenzaldehyde I
identified O
in O
the O
roots O
as O
the O
most O
abundant O
component O
( O
70 O
. O
7 O
% O
) O
and O
present O
with O
8 O
. O
3 O
% O
in O
the O
branches O
is O
a O
potent O
tyrosinase O
inhibitor O
present O
in O
several O
African O
medicinal O
plants O
, O
and O
thus O
being O
used O
as O
an O
ingredient O
in O
cosmetic O
and O
other O
medicinal O
products O
, O
primarily O
in O
relation O
to O
hyperpigmentation O
. O

dihydroxyoleane I
- I
12 I
- I
ene I
- I
28 I
- I
oic I
acid I
) O
, O
betulin B
and O
lupeol B
. O

We O
herein O
demonstrate O
that O
in O
addition O
to O
non O
- O
selective O
group O
II O
mGlu O
receptor O
agonists O
, O
( B
2R I
, I
4R I
) I
- I
APDC I
, O
LY379268 B
and O
DCG B
- I
IV I
, O
a O
selective O
mGlu2 O
agonist O
, O
LY541850 B
, O
and O
mGlu2 O
positive O
allosteric O
modulators O
, O
BINA O
and O
CBiPES O
, O
inhibit O
the O
frequency O
of O
synchronised O
Ca B
( I
2 I
+ I
) I
oscillations O
in O
primary O
cultures O
of O
rat O
and O
mouse O
cortical O
neurons O
. O

Purified O
synaptosomes O
were O
selectively O
prelabeled O
with O
[ B
( I
3 I
) I
H I
] I
glycine I
through O
the O
neuronal O
transporter O
GlyT2 O
and O
subsequently O
depolarized O
by O
superfusion O
with O
12 O
mM O
KCl B
. O

The O
selective O
mGluR2 O
/ O
3 O
agonist O
LY379268 B
inhibited O
the O
K B
( I
+ I
) I
- O
evoked O
overflow O
of O
[ B
( I
3 I
) I
H I
] I
glycine I
in O
a O
concentration O
- O
dependent O
manner O
( O
EC O
( O
50 O
) O
about O
0 O
. O
2 O
nM O
) O
. O

N B
- I
acetylaspartylglutam I
( O
NAAG B
) O
inhibited O
[ B
( I
3 I
) I
H I
] I
glycine I
overflow O
with O
extraordinary O
potency O
( O
EC O
( O
50 O
) O
about O
50 O
fmol O
) O
. O

LY341495 B
antagonized O
the O
NAAG B
inhibition O
of O
[ B
( I
3 I
) I
H I
] I
glycine I
release O
. O

n B
- I
Butyl I
- I
p I
- I
hydroxybenzoate I
( O
n B
- I
butylparaben I
, O
BPB B
) O
is O
an O
antioxidant O
used O
in O
foods O
, O
pharmaceuticals O
and O
cosmetics O
. O

This O
study O
investigated O
the O
disposition O
of O
ring O
- O
labelled O
[ B
( I
14 I
) I
C I
] I
BPB I
in O
Harlan O
Sprague O
Dawley O
rats O
, O
and O
in O
rat O
and O
human O
hepatocytes O
. O

[ B
( I
14 I
) I
C I
] I
BPB I
was O
administered O
to O
male O
rats O
orally O
at O
10 O
, O
100 O
or O
1000 O
mg O
/ O
kg O
, O
intravenously O
at O
10 O
mg O
/ O
kg O
and O
dermally O
at O
10 O
and O
100 O
mg O
/ O
kg O
; O
female O
rats O
were O
administered O
oral O
doses O
at O
10 O
mg O
/ O
kg O
. O

Gelucires O
are O
polyethylene B
glycol I
( O
PEG B
) O
glycerides O
composed O
of O
mono B
- I
, I
di I
- I
and I
triglycerides I
and O
mono O
- O
and O
diesters O
of O
PEG B
. O

Metabotropic O
glutamate B
5 O
( O
mGlu O
5 O
) O
receptors O
are O
known O
to O
functionally O
interact O
with O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
receptors O
at O
both O
neuronal O
and O
behavioural O
levels O
, O
in O
a O
manner O
that O
may O
be O
of O
relevance O
to O
the O
treatment O
of O
schizophrenia O
. O

The O
demonstrated O
functional O
interaction O
of O
metabotropic O
glutamate B
5 O
( O
mGlu O
5 O
) O
receptors O
with O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
receptors O
has O
prompted O
speculation O
that O
their O
activation O
may O
offer O
a O
potential O
treatment O
for O
aspects O
of O
schizophrenia O
. O

Both O
compounds O
displaced O
the O
mGlu O
5 O
receptor O
antagonist O
radioligand O
, O
[ B
( I
3 I
) I
H I
] I
MPEP I
in O
vitro O
and O
, O
following O
oral O
administration O
reached O
brain O
concentrations O
sufficient O
to O
occupy O
hippocampal O
mGlu O
5 O
receptors O
as O
measured O
in O
vivo O
by O
dose O
- O
dependent O
displacement O
from O
the O
hippocampus O
of O
intravenously O
administered O
MPEPy B
. O

N B
- I
p I
- I
methoxy I
cinnamoyl I
serotonin I
( O
3 O
) O
was O
converted O
into O
its O
O B
- O
demethylated O
compound O
, O
N B
- I
p I
- I
coumaroyl I
serotonin I
( O
2 O
) O
. O

Theoretical O
study O
of O
the O
decomposition O
of O
ethyl B
and I
ethyl I
3 I
- I
phenyl I
glycidate I
. O

The O
mechanism O
of O
the O
decomposition O
of O
ethyl B
and I
ethyl I
3 I
- I
phenyl I
glycidate I
in O
gas O
phase O
was O
studied O
by O
density O
functional O
theory O
( O
DFT O
) O
and O
MP2 O
methods O
. O

Metabotropic O
glutamate B
- O
5 O
receptors O
( O
mGluR5 O
) O
, O
which O
physically O
and O
functionally O
interact O
with O
N B
- I
methyl I
- I
D I
- I
Aspartate I
( O
NMDA B
) O
receptors O
, O
likewise O
control O
cognitive O
processes O
and O
have O
been O
proposed O
as O
targets O
for O
novel O
classes O
of O
antipsychotic O
agent O
. O

L B
- I
and I
D I
- I
amino I
acids I
have O
diverse O
functions O
and O
effects O
on O
the O
metabolism O
, O
growth O
, O
and O
development O
of O
plants O
. O

As O
a O
hallmark O
, O
the O
unusual O
monofucosylated B
N I
, I
N I
' I
- I
diacetylhexosediamin I
( O
tentatively O
assigned O
as O
GalNAc B
beta I
1 I
- I
- I
> I
4GlcNAc I
, O
LacdiNAc B
) O
modification O
was O
detected O
as O
the O
terminal O
structure O
of O
a O
bi O
- O
antennary O
complex O
type O
N B
- O
glycan O
exhibiting O
also O
core O
fucosylation O
. O

As O
a O
hallmark O
, O
the O
unusual O
monofucosylated B
N I
, I
N I
' I
- I
diacetylhexosediamin I
( O
tentatively O
assigned O
as O
GalNAc B
beta I
1 I
- I
- I
> I
4GlcNAc I
, O
LacdiNAc B
) O
modification O
was O
detected O
as O
the O
terminal O
structure O
of O
a O
bi O
- O
antennary O
complex O
type O
N B
- O
glycan O
exhibiting O
also O
core O
fucosylation O
. O

Dimethyl B
sulphide I
, O
1 B
- I
penten I
- I
3 I
- I
ol I
, O
1 B
- I
hexen I
- I
3 I
- I
ol I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
during O
storage O
, O
whereas O
pentanal B
, O
hexanal B
, O
heptanal B
, O
octanal B
and O
3 B
- I
undecen I
- I
2 I
- I
one I
decreased O
. O

Dimethyl B
sulphide I
, O
1 B
- I
penten I
- I
3 I
- I
ol I
, O
1 B
- I
hexen I
- I
3 I
- I
ol I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
during O
storage O
, O
whereas O
pentanal B
, O
hexanal B
, O
heptanal B
, O
octanal B
and O
3 B
- I
undecen I
- I
2 I
- I
one I
decreased O
. O

Dimethyl B
sulphide I
, O
1 B
- I
penten I
- I
3 I
- I
ol I
, O
1 B
- I
hexen I
- I
3 I
- I
ol I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
during O
storage O
, O
whereas O
pentanal B
, O
hexanal B
, O
heptanal B
, O
octanal B
and O
3 B
- I
undecen I
- I
2 I
- I
one I
decreased O
. O

Dimethyl B
sulphide I
, O
1 B
- I
penten I
- I
3 I
- I
ol I
, O
1 B
- I
hexen I
- I
3 I
- I
ol I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
during O
storage O
, O
whereas O
pentanal B
, O
hexanal B
, O
heptanal B
, O
octanal B
and O
3 B
- I
undecen I
- I
2 I
- I
one I
decreased O
. O

Vitamin B
D I
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 B
- I
hydroxyvitamin I
D I
3 I
( O
25 B
( I
OH I
) I
D I
3 I
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
( O
1 B
, I
25 I
( I
OH I
) I
2 I
D I
3 I
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium B
absorption O
from O
the O
gut O
. O

2 O
. O
Urine O
was O
collected O
from O
three O
male O
Wistar O
rats O
for O
24 O
h O
after O
dosing O
with O
( B
14 I
) I
C I
- I
labelled I
lesogaberan I
( O
170 O
mg O
/ O
kg O
, O
10 O
MBq O
/ O
kg O
) O
; O
plasma O
samples O
were O
taken O
2 O
and O
24 O
h O
after O
dosing O
. O

Hexagonal O
tris B
( I
o I
- I
phenylenedioxy I
) I
cyclotriphosphazene I
( O
TPP B
) O
is O
used O
as O
ahost O
for O
organizing O
dipolar O
molecular O
rotor O
guests O
into O
regular O
trigonal O
arrays O
. O

Ketamine B
- O
induced O
neuronal O
damage O
and O
altered O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
function O
in O
rat O
primary O
forebrain O
culture O
. O

Ketamine B
, O
a O
noncompetitive O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonist O
, O
is O
frequently O
used O
in O
pediatric O
general O
anesthesia O
. O

Pharmacokinetics O
and O
metabolism O
of O
[ B
( I
14 I
) I
C I
] I
anagliptin I
, O
a O
novel O
dipeptidyl O
peptidase O
- O
4 O
inhibitor O
, O
in O
humans O
. O

1 O
. O
The O
disposition O
of O
anagliptin B
, O
an O
orally O
active O
, O
highly O
selective O
dipeptidyl O
peptidase O
- O
4 O
inhibitor O
, O
was O
investigated O
after O
a O
single O
oral O
dose O
of O
100 O
mg O
/ O
1 O
. O
92 O
MBq O
[ B
( I
14 I
) I
C I
] I
anagliptin I
to O
six O
healthy O
men O
. O

On O
days O
1 O
and O
8 O
, O
BALB O
/ O
c O
mice O
received O
dermal O
applications O
with O
toluene B
- I
2 I
, I
4 I
- I
diisocyanate I
( O
TDI B
) O
or O
vehicle O
( O
acetone B
olive O
oil O
) O
, O
followed O
by O
two O
ip O
injections O
of O
cyclophosphamide B
( O
CP O
, O
days O
11 O
and O
13 O
) O
, O
or O
one O
iv O
injection O
of O
antigranulocyte O
receptor O
1 O
( O
aGR1 O
, O
day O
13 O
) O
monoclonal O
antibody O
( O
mAb O
) O
, O
or O
two O
ip O
injections O
of O
Ly6G O
- O
specific O
mAb O
( O
1A8 O
, O
days O
13 O
and O
14 O
) O

In O
contrast O
to O
A B
alpha I
- I
and I
A I
beta I
BA I
, O
beta B
BA I
and O
alpha B
BA I
were O
intensively O
metabolized O
after O
incubation O
with O
human O
and O
rat O
liver O
microsomes O
. O

[ B
+ I
] I
- I
Hup I
A I
block O
the O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino B
acid I
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O

Angiotensin B
- I
( I
1 I
- I
7 I
) I
modulates O
renin O
- O
angiotensin O
system O
associated O
with O
reducing O
oxidative O
stress O
and O
attenuating O
neuronal O
apoptosis O
in O
the O
brain O
of O
hypertensive O
rats O
. O

Angiotensin B
- I
( I
1 I
- I
7 I
) I
[ O
Ang B
- I
( I
1 I
- I
7 I
) I
] O
has O
beneficial O
effects O
against O
hypertension O
- O
induced O
damage O
in O
heart O
and O
kidney O
, O
but O
its O
effects O
in O
brain O
are O
not O
clear O
as O
yet O
. O

Angiotensin B
- I
( I
1 I
- I
7 I
) I
[ O
Ang B
- I
( I
1 I
- I
7 I
) I
] O
has O
beneficial O
effects O
against O
hypertension O
- O
induced O
damage O
in O
heart O
and O
kidney O
, O
but O
its O
effects O
in O
brain O
are O
not O
clear O
as O
yet O
. O

The O
present O
study O
aimed O
to O
investigate O
the O
protective O
effects O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
on O
the O
physiopathologic O
changes O
caused O
by O
hypertension O
in O
brain O
of O
spontaneously O
hypertensive O
rats O
( O
SHRs O
) O
. O

Wistar O
- O
Kyoto O
rats O
received O
intracerebroventricu O
( O
I O
. O
C O
. O
V O
. O
) O
infusion O
of O
artificial O
cerebrospinal O
fluid O
( O
aCSF O
) O
while O
SHRs O
received O
I O
. O
C O
. O
V O
. O
infusion O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
, O
Mas O
receptor O
antagonist O
A O
- O
779 O
and O
aCSF O
for O
4 O
weeks O
. O

Our O
study O
showed O
that O
infusion O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
for O
4 O
weeks O
significantly O
reduced O
the O
expression O
of O
Angiotensin B
II I
and O
Angiotensin B
II I
type O
1 O
receptors O
in O
SHR O
brain O
. O

The O
increases O
of O
the O
percentage O
of O
TUNEL O
- O
positive O
neurons O
and O
Bax O
to O
Bcl O
- O
2 O
ratio O
in O
SHR O
brain O
were O
also O
attenuated O
by O
Ang B
- I
( I
1 I
- I
7 I
) I
. O

The O
anti O
- O
oxidative O
and O
anti O
- O
apoptosis O
effects O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
are O
independent O
of O
blood O
pressure O
reduction O
and O
can O
be O
partially O
abolished O
by O
A O
- O
779 O
. O

These O
findings O
suggest O
that O
chronic O
treatment O
with O
Ang B
- I
( I
1 I
- I
7 I
) I
is O
beneficial O
to O
attenuate O
hypertension O
- O
induced O
physiopathologic O
changes O
in O
brain O
and O
may O
be O
helpful O
to O
prevent O
hypertension O
- O
related O
cerebrovascular O
diseases O
. O

The O
structural O
analysis O
showed O
that O
lipids O
bind O
dendrimers O
through O
both O
hydrophilic O
and O
hydrophobic O
contacts O
with O
overall O
binding O
constants O
of O
K O
( O
chol B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
2 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
0 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
G3 I

) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
3 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
9 O
x O
10 O
( O

2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
PAMAM I
- I
G4 I
) O
= O
7 O
. O
0 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
9 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
and O
K O
( O
DOTAP B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
7 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
. O

The O
free O
binding O
energies O
from O
docking O
were O
- O
5 O
. O
15 O
( O
cholesterol B
) O
, O
- O
5 O
. O
79 O
( O
DDAB B
) O
, O
and O
- O
5 O
. O
36 O
kcal O
/ O
mol O
( O
DOTAP B
) O
with O
the O
order O
of O
stability O
DDAB B
- I
PAMAM I
- I
G I
- I
4 I
> O
DOTAP B
- I
PAMAM I
- I
G4 I
> O
cholesterol B
- O
PAMAM B
- I
G4 I
, O
consistent O
with O
the O
spectroscopic O
results O
. O

Cytotoxic O
evaluation O
against O
a O
panel O
of O
cancer O
cell O
lines O
uncovered O
the O
stereochemical O
and O
substitutional O
limits O
of O
the O
C3 B
' I
/ I
C4 I
' I
- I
hydroxy I
functionality O
in O
digitoxin B
monosaccharide B
. O

The O
latter O
rapidly O
converts O
to O
2 B
, I
2 I
- I
diamino I
- I
oxazolone I
( O
Ox O
) O
, O
and O
8 B
- I
oxodG I
is O
further O
oxidized O
to O
spiroiminodihydantoi B
( O
Sp O
) O
and O
guanidinohydantoin B
( O
Gh O
) O
. O

Protein O
expression O
of O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptors O
( O
NR1 O
, O
NR2A O
, O
NR2B O
) O
, O
calmodulin O
- O
dependent O
protein O
kinase O
II O
( O
CaMKII O
) O
and O
adenylate B
cyclase O
( O
AC O
) O
in O
neurons O
were O
measured O
after O
incubation O
with O
ACM O
for O
4 O
, O
8 O
or O
12 O
h O
. O

The O
most O
promising O
radioligand O
for O
D O
( O
2 O
) O
/ O
D O
( O
3 O
) O
neuroreceptor O
imaging O
is O
the O
agonist O
[ B
( I
11 I
) I
C I
] I
PHNO I
, O
with O
higher O
in O
vivo O
affinity O
for O
D O
( O
3 O
) O
than O
D O
( O
2 O
) O
receptors O
, O
which O
can O
be O
used O
to O
measure O
amphetamine B
- O
induced O
release O
of O
dopamine B
, O
and O
therefore O
a O
potential O
model O
of O
dopaminergic O
alterations O
in O
schizophrenia O
. O

Recent O
development O
of O
selective O
radiotracers O
allow O
imaging O
of O
the O
serotonin B
transporter O
( O
SERT O
) O
using O
positron O
emission O
tomography O
( O
PET O
) O
with O
selective O
tracers O
such O
as O
[ B
( I
11 I
) I
C I
] I
DASB I
. O

Simultaneous O
ectopic O
overexpression O
of O
RBCK1 O
and O
PXR O
decreased O
PXR O
levels O
in O
AD O
- O
293 O
cells O
, O
and O
this O
decrease O
was O
inhibited O
by O
the O
proteasomal O
inhibitor O
MG B
- I
132 I
( O
carbobenzoxy B
- I
Leu I
- I
Leu I
- I
leucinal I
) O
. O

The O
resistance O
lowered O
the O
sensitivity O
toward O
cellular O
damages O
evoked O
by O
oxidative O
stress O
- O
derived O
aldehydes B
, O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
and O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
that O
are O
detoxified O
by O
AKR1C1 O
and O
AKR1C3 O
. O

The O
resistance O
lowered O
the O
sensitivity O
toward O
cellular O
damages O
evoked O
by O
oxidative O
stress O
- O
derived O
aldehydes B
, O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
and O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
that O
are O
detoxified O
by O
AKR1C1 O
and O
AKR1C3 O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

A O
comparison O
with O
results O
from O
recent O
crossed O
molecular O
beam O
studies O
of O
the O
1 B
, I
3 I
- I
butadiene I
- I
phenyl I
radical O
reaction O
and O
electronic O
structure O
calculations O
suggests O
that O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
( O
130 O
amu O
) O
, O
1 B
, I
4 I
- I
dihydronaphthalene I
( O
130 O
amu O
) O
, O
and O
styrene B
( O
104 O
amu O
) O
are O
reaction O
products O
formed O
as O
a O
consequence O
of O
a O
bimolecular O
reaction O
between O
the O
phenyl B
radical O
and O
1 B
, I
3 I
- I
butadiene I
. O

A O
comparison O
with O
results O
from O
recent O
crossed O
molecular O
beam O
studies O
of O
the O
1 B
, I
3 I
- I
butadiene I
- I
phenyl I
radical O
reaction O
and O
electronic O
structure O
calculations O
suggests O
that O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
( O
130 O
amu O
) O
, O
1 B
, I
4 I
- I
dihydronaphthalene I
( O
130 O
amu O
) O
, O
and O
styrene B
( O
104 O
amu O
) O
are O
reaction O
products O
formed O
as O
a O
consequence O
of O
a O
bimolecular O
reaction O
between O
the O
phenyl B
radical O
and O
1 B
, I
3 I
- I
butadiene I
. O

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

1H B
NMR O
spectra O
of O
ethane B
- I
1 I
, I
2 I
- I
diol I
and O
other O
vicinal B
diols I
in O
benzene B
: O
GIAO O
/ O
DFT O
shift O
calculations O
. O

The O
shifts O
and O
coupling O
constants O
of O
the O
OH B
and O
methylene B
protons O
of O
ethane B
- I
1 I
, I
2 I
- I
diol I
have O
been O
determined O
in O
a O
wide O
range O
of O
solvents O
. O

Previous O
calculations O
on O
ethane B
- I
1 I
, I
2 I
- I
diol I
and O
propane B
- I
1 I
, I
2 I
- I
diol I
have O
been O
corrected O
and O
extended O
. O

Previous O
calculations O
on O
ethane B
- I
1 I
, I
2 I
- I
diol I
and O
propane B
- I
1 I
, I
2 I
- I
diol I
have O
been O
corrected O
and O
extended O
. O

New O
calculations O
on O
tert B
- I
butylethane I
- I
1 I
, I
2 I
- I
diol I
, O
phenylethane B
- I
1 I
, I
2 I
- I
diol I
, O
butane B
- I
2 I
, I
3 I
- I
diols I
( O
dl O
and O
meso O
) O
and O
cyclohexane B
- I
1 I
, I
2 I
- I
diols I
( O
cis O
and O
trans O
) O
are O
presented O
. O

New O
calculations O
on O
tert B
- I
butylethane I
- I
1 I
, I
2 I
- I
diol I
, O
phenylethane B
- I
1 I
, I
2 I
- I
diol I
, O
butane B
- I
2 I
, I
3 I
- I
diols I
( O
dl O
and O
meso O
) O
and O
cyclohexane B
- I
1 I
, I
2 I
- I
diols I
( O
cis O
and O
trans O
) O
are O
presented O
. O

New O
calculations O
on O
tert B
- I
butylethane I
- I
1 I
, I
2 I
- I
diol I
, O
phenylethane B
- I
1 I
, I
2 I
- I
diol I
, O
butane B
- I
2 I
, I
3 I
- I
diols I
( O
dl O
and O
meso O
) O
and O
cyclohexane B
- I
1 I
, I
2 I
- I
diols I
( O
cis O
and O
trans O
) O
are O
presented O
. O

We O
now O
report O
that O
levulinate B
forms O
three O
seven O
- O
carbon B
cyclical O
CoA O
esters O
by O
processes O
starting O
with O
the O
elongation O
of O
levulinyl B
- I
CoA I
by O
acetyl B
- I
CoA I
to O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
. O

The O
second O
cyclization O
process O
yields O
a O
methyl B
- I
pyrrolyl I
- I
acetyl I
- I
CoA I
containing O
a O
nitrogen B
atom O
derived O
from O
the O
epsilon B
- I
nitrogen I
of O
lysine B
but O
without O
carbons B
from O
lysine B
. O

Lastly O
, O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
, O
like O
2 B
, I
5 I
- I
diketohexane I
, O
pyrrolates B
free O
lysine B
and O
, O
presumably O
, O
lysine B
residues O
from O
proteins O
. O

Novel O
2 B
- I
aminooctahydrocyclop I
- I
3a I
- I
carboxamides I
as O
potent O
CCR2 O
antagonists O
. O

Novel O
CCR2 O
antagonists O
with O
a O
novel O
2 B
- I
aminooctahydrocyclop I
- I
3a I
- I
carboxamide I
scaffold O
were O
designed O
. O

Ion O
pair O
dynamics O
: O
solvolyses O
of O
chiral B
1 I
, I
3 I
- I
diarylallyl I
carboxylates I
as O
a O
case O
study O
. O

Although O
the O
solutions O
containing O
H B
( I
2 I
) I
CO I
( I
3 I
) I
, O
Cl B
( I
- I
) I
, O
ClO B
( I
4 I
) I
( I
- I
) I
, O
NO B
( I
3 I
) I
( I
- I
) I
and O
SO B
( I
4 I
) I
( I
2 I
- I
) I
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H B
( I
2 I
) I
PO I
( I
4 I
) I
( I
- I
) I
ion O
did O
decrease O
the O
decolouration O
rate O
. O

Although O
the O
solutions O
containing O
H B
( I
2 I
) I
CO I
( I
3 I
) I
, O
Cl B
( I
- I
) I
, O
ClO B
( I
4 I
) I
( I
- I
) I
, O
NO B
( I
3 I
) I
( I
- I
) I
and O
SO B
( I
4 I
) I
( I
2 I
- I
) I
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H B
( I
2 I
) I
PO I
( I
4 I
) I
( I
- I
) I
ion O
did O
decrease O
the O
decolouration O
rate O
. O

The O
main O
anthocyanins B
were O
3 B
- I
sophoroside I
- I
5 I
- I
glucoside I
derivatives O
from O
cyanidin B
and O
peonidin B
, O
acylated O
with O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
or O
caffeic B
acid I
. O

A O
unique O
anthocyanin B
, O
delphinidin B
- I
3 I
, I
5 I
- I
diglucoside I
was O
also O
found O
. O

Their O
electron O
impact O
mass O
spectra O
are O
compatible O
with O
16 B
- I
hydroxylated I
steroids I
O I
- I
TMS I
derivatives O
presenting O
diagnostic O
ions O
such O
as O
m O
/ O
z O
231 O
and O
m O
/ O
z O
218 O
. O

Significantly O
, O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
hierarchical O
nanostructures O
as O
the O
tricomponent O
heterojunction O
system O
possessed O
stronger O
photocatalytic O
activity O
than O
the O
bicomponent O
heterojunction O
system O
of O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
A I
) I
hierarchical O
nanostructures O
or O
TiO B
( I
2 I
) I
( I
AR I
) I
nanofibers O
, O
which O
was O
discussed O
in O
terms O
of O
the O
three O
- O
way O
photosynergistic O
effect O
between O
SnS B
( I
2 I
) I
, O
TiO B
( I
2 I

Significantly O
, O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
hierarchical O
nanostructures O
as O
the O
tricomponent O
heterojunction O
system O
possessed O
stronger O
photocatalytic O
activity O
than O
the O
bicomponent O
heterojunction O
system O
of O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
A I
) I
hierarchical O
nanostructures O
or O
TiO B
( I
2 I
) I
( I
AR I
) I
nanofibers O
, O
which O
was O
discussed O
in O
terms O
of O
the O
three O
- O
way O
photosynergistic O
effect O
between O
SnS B
( I
2 I
) I
, O
TiO B
( I
2 I

Significantly O
, O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
hierarchical O
nanostructures O
as O
the O
tricomponent O
heterojunction O
system O
possessed O
stronger O
photocatalytic O
activity O
than O
the O
bicomponent O
heterojunction O
system O
of O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
A I
) I
hierarchical O
nanostructures O
or O
TiO B
( I
2 I
) I
( I
AR I
) I
nanofibers O
, O
which O
was O
discussed O
in O
terms O
of O
the O
three O
- O
way O
photosynergistic O
effect O
between O
SnS B
( I
2 I
) I
, O
TiO B
( I
2 I

) I
( I
A I
) I
and O
TiO B
( I
2 I
) I
( I
R I
) I
component O
in O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
heterojunction O
resulting O
in O
the O
high O
separation O
efficiency O
of O
photoinduced O
electron O
- O
hole O
pairs O
, O
as O
evidenced O
by O
photoluminescence O
( O
PL O
) O
and O
surface O
photovoltage O
spectra O
( O
SPS O
) O
. O

Identification O
of O
ginkgolic B
acid I
( I
15 I
: I
1 I
) I
metabolites O
in O
rats O
following O
oral O
administration O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
. O

CA O
- O
OH B
was O
used O
both O
for O
homopolymerization O
of O
ethylene B
oxide I
( O
EO O
) O
as O
well O
as O
copolymerization O
with O
functional O
epoxides B
N B
, I
N I
- I
diallyl I
glycidyl I
amine I
( O
DAGA B
) O
, O
releasing O
primary B
amino I
groups O
and O
ethylene B
glycol I
vinyl I
glycidyl I
ether I
( O
EVGE B
) O
, O
exhibiting O
a O
double O
bond O
for O
click O
- O
type O
reactions O
, O
to O
generate O
CA O
- O
PEG B
and O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
. O

The O
present O
study O
investigated O
the O
effect O
of O
neonatal O
exposure O
to O
diazinon B
on O
hippocampus O
- O
dependent O
novel O
object O
recognition O
test O
performance O
and O
the O
expression O
of O
the O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
and O
its O
signal O
transduction O
pathway O
- O
related O
genes O
in O
the O
hippocampi O
of O
young O
adult O
and O
adult O
mice O
. O

This O
inductive O
effect O
was O
blocked O
by O
the O
addition O
of O
6 B
' I
, I
7 I
' I
- I
dihydroxybergamottin I
, O
a O
selective O
CYP3A4 O
inhibitor O
. O

We O
have O
synthesized O
a O
series O
of O
potent O
FAAH O
inhibitors O
encompassing O
two O
classes O
of O
N B
- I
alkyl I
- I
O I
- I
arylcarbamates I
and O
radiolabeled O
eight O
of O
them O
with O
carbon B
- I
11 I
. O

Analysis O
of O
the O
particle O
formation O
as O
a O
function O
of O
irradiation O
time O
shows O
that O
the O
particles O
evolve O
from O
Co B
( I
OH I
) I
( I
2 I
) I
to O
CoOOH B
and O
then O
to O
Co B
( I
3 I
) I
O I
( I
4 I
) I
. O

A O
key O
factor O
is O
the O
low O
solubility O
of O
Co B
( I
OH I
) I
( I
2 I
) I
in O
air O
- O
saturated O
solutions O
at O
high O
pH O
. O

Complexes O
smaller O
than O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
cannot O
be O
formed O
in O
this O
source O
because O
charge O
separation O
into O
MgOH B
( I
+ I
) I
( I
H2O I
) I
and O
H3O B
( I
+ I
) I
is O
a O
lower O
- O
energy O
pathway O
than O
simple O
water O
loss O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
. O

In O
this O
study O
, O
well O
- O
defined O
poly B
( I
glycidyl I
methacrylate I
) I
( O
P B
( I
GMA I
) I
) O
homopolymers O
were O
synthesized O
using O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
followed O
by O
decoration O
using O
three O
different O
types O
of O
oligoamines B
, O
i O
. O
e O
. O
, O
tetraethylenepentami B
( O
TEPA B
) O
, O
pentaethylenehexamin B
( O
PEHA B
) O
, O
and O
tris B
( I
2 I
- I
aminoethyl I
) I
amine I
( O
TREN B
) O
, O
respectively O
, O
to O
generate O
various O
P B
( I
GMA I
- I
oligoamine I
) I

5 B
' I
- I
Beta I
enzylglycinyl I
- I
amiloride I
( O
UCD38B B
) O
and O
glycinyl B
- I
amiloride I
( O
UCD74A B
) O
are O
cell O
- O
permeant O
and O
cell O
- O
impermeant O
derivatives O
of O
amiloride B
, O
respectively O
, O
and O
used O
here O
to O
identify O
the O
cellular O
mechanisms O
of O
action O
underlying O
their O
antiglioma O
effects O
. O

The O
three O
- O
step O
approach O
of O
CliEn O
- O
seq O
involves O
in O
vivo O
synthesis O
of O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( O
SAM B
) O
analogues O
from O
cell O
- O
permeable O
methionine B
analogues O
by O
engineered O
SAM B
synthetase O
( O
methionine B
adenosyltransferase O
or O
MAT O
) O
, O
in O
situ O
chromatin O
modification O
by O
engineered O
PMTs O
, O
subsequent O
enrichment O
and O
sequencing O
of O
the O
uniquely O
modified O
chromatins O
. O

The O
association O
constants O
for O
the O
formation O
of O
anion O
- O
pi O
complexes O
in O
acetonitrile B
are O
in O
the O
range O
of O
239 O
to O
16950 O
M O
( O
- O
1 O
) O
, O
following O
the O
order O
of O
1 O
. O
NO B
( I
3 I
) I
( I
- I
) I
> O
1 O
. O
BF B
( I
4 I
) I
( I
- I
) I
> O
1 O
. O
PF B
( I
6 I
) I
( I
- I
) I
> O
1 O
. O
SCN B
( I
- I
) I
. O

The O
association O
constants O
for O
the O
formation O
of O
anion O
- O
pi O
complexes O
in O
acetonitrile B
are O
in O
the O
range O
of O
239 O
to O
16950 O
M O
( O
- O
1 O
) O
, O
following O
the O
order O
of O
1 O
. O
NO B
( I
3 I
) I
( I
- I
) I
> O
1 O
. O
BF B
( I
4 I
) I
( I
- I
) I
> O
1 O
. O
PF B
( I
6 I
) I
( I
- I
) I
> O
1 O
. O
SCN B
( I
- I
) I
. O

The O
association O
constants O
for O
the O
formation O
of O
anion O
- O
pi O
complexes O
in O
acetonitrile B
are O
in O
the O
range O
of O
239 O
to O
16950 O
M O
( O
- O
1 O
) O
, O
following O
the O
order O
of O
1 O
. O
NO B
( I
3 I
) I
( I
- I
) I
> O
1 O
. O
BF B
( I
4 I
) I
( I
- I
) I
> O
1 O
. O
PF B
( I
6 I
) I
( I
- I
) I
> O
1 O
. O
SCN B
( I
- I
) I
. O

Dual O
action O
spirobicycloimidazol B
- I
2 I
, I
4 I
- I
diones I
: O
antidiabetic O
agents O
and O
inhibitors O
of O
aldose B
reductase O
- O
an O
enzyme O
involved O
in O
diabetic O
complications O
. O

The O
desired O
3 B
- I
( I
arylsulfonyl I
) I
spiroimidazolidine I
- I
2 I
, I
4 I
- I
diones I
were O
synthesized O
by O
reacting O
spiroiminoimidazolid B
- I
2 I
, I
4 I
- I
dione I
with O
arylsulfonyl B
chlorides I
. O

Spiroimidazolidine B
- I
2 I
, I
4 I
- I
dione I
was O
in O
turn O
synthesized O
from O
norcamphor B
. O

In O
HEK O
- O
OATP1B1 O
* O
15 O
cells O
, O
the O
V O
( O
max O
) O
for O
OATP1B1 O
- O
mediated O
transport O
of O
E O
( O
2 O
) O
17 O
beta O
- O
G O
( O
estradiol B
17 I
beta I
- I
d I
- I
glucuronide I
) O
was O
decreased O
> O
60 O
% O
, O
whereas O
K O
( O
m O
) O
values O
( O
Michaelis O
constant O
) O
were O
comparable O
. O

An O
oxycodone B
hapten O
containing O
a O
tetraglycine B
linker O
at O
the O
C6 O
position O
( O
6OXY B
( I
Gly I
) I
( I
4 I
) I
OH I
) O
conjugated O
to O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
has O
shown O
early O
proof O
- O
of O
- O
efficacy O
in O
rodents O
as O
a O
candidate O
immunogen O
( O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
) O
for O
the O
treatment O
of O
oxycodone B
abuse O
. O

Vaccination O
with O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
increased O
drug O
binding O
in O
serum O
, O
reduced O
drug O
distribution O
to O
brain O
, O
and O
blunted O
analgesia O
for O
both O
oxycodone B
and O
hydrocodone B
. O

An O
analogous O
C6 O
- O
linked O
hydrocodone B
vaccine O
blocked O
hydrocodone B
effects O
but O
less O
so O
than O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
. O

The O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
vaccine O
may O
be O
used O
for O
treatment O
of O
prescription O
opioid O
abuse O
. O

When O
ether B
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solution O
of O
an O
enantiomer O
of O
a O
hexa B
- I
peri I
- I
hexabenzocoronene I
( O
HBC B
) O
derivative O
carrying O
a O
chiral O
( B
BINAP I
) I
Pt I
( I
II I
) I
- O
appended O
coordination O
metallacycle O
( O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) O
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendant O
. O

Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendant O
. O

Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendant O
. O

Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendant O
. O

Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendant O
. O

Removal O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendants O
from O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
with O
ethylenediamine B
yielded O
metal O
- O
free O
nanotubes O
( O
NT O
( O
Py B
) O
) O
that O
remained O
optically O
active O
even O
upon O
heating O
without O
any O
change O
in O
the O
circular O
dichroism O
spectral O
profile O
. O

Removal O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendants O
from O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
with O
ethylenediamine B
yielded O
metal O
- O
free O
nanotubes O
( O
NT O
( O
Py B
) O
) O
that O
remained O
optically O
active O
even O
upon O
heating O
without O
any O
change O
in O
the O
circular O
dichroism O
spectral O
profile O
. O

Removal O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendants O
from O
NT O
( O
Py B
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py B
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
with O
ethylenediamine B
yielded O
metal O
- O
free O
nanotubes O
( O
NT O
( O
Py B
) O
) O
that O
remained O
optically O
active O
even O
upon O
heating O
without O
any O
change O
in O
the O
circular O
dichroism O
spectral O
profile O
. O

No O
helical O
inversion O
took O
place O
when O
NT O
( O
Py B
) O
derived O
from O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) I
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
was O
allowed O
to O
complex O
with O
( B
BINAP I
) I
Pt I
( I
II I
) I
with O
an O
absolute O
configuration O
opposite O
to O
the O
original O
one O
. O

We O
present O
here O
the O
structure O
- O
based O
design O
and O
synthesis O
of O
new O
cathepsin O
B O
inhibitors O
using O
the O
cocrystal O
structure O
of O
5 B
- I
nitro I
- I
8 I
- I
hydroxyquinoline I
in O
the O
cathepsin O
B O
active O
site O
. O

Molecular O
nonwoven O
fabrics O
in O
the O
form O
of O
ultrathin O
layer O
- O
by O
- O
layer O
( O
LbL O
) O
helical O
polymer O
films O
with O
covalent O
cross O
- O
linking O
were O
assembled O
on O
substrates O
by O
an O
alternate O
ester B
- O
amide B
exchange O
reaction O
between O
poly B
( I
gamma I
- I
methyl I
l I
- I
glutamate I
) I
( O
PMLG B
) O
and O
cross O
- O
linking O
agent O
ethylene B
diamine I
or O
4 B
, I
4 I
' I
- I
diamino I
azobenzene I
. O

However O
, O
the O
ethylenic B
analogue O
was O
more O
effective O
than O
the O
cyclopropyl B
one O
in O
the O
melanophore O
aggregation O
bioassay O
, O
but O
was O
still O
less O
potent O
than O
the O
disubstituted O
2 B
, I
7 I
- I
dimethoxy I
- I
naphtalenic I
compounds O
. O

Dietary O
supplementation O
with O
omega B
- I
3 I
long I
chain I
fatty I
acids I
including O
docosahexaenoic B
acid I
( O
DHA B
) O
has O
increased O
in O
popularity O
in O
recent O
years O
and O
adequate O
DHA B
supplementation O
during O
pregnancy O
and O
early O
childhood O
is O
of O
clinical O
importance O
. O

This O
study O
assesses O
hydroxyl B
radical O
( O
OH B
) O
generation O
and O
measures O
malondialdehyde B
( O
MDA B
) O
levels O
in O
the O
cerebral O
tissue O
of O
rats O
exposed O
to O
six O
solvents O
( O
n B
- I
hexane I
, O
n B
- I
octane I
, O
toluene B
, O
n B
- I
butylbenzene I
, O
cyclohexane B
and O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
) O
. O

On O
the O
other O
hand O
, O
a O
decrease O
in O
the O
concentrations O
of O
free O
MDA B
in O
brain O
structures O
was O
observed O
after O
acute O
administration O
of O
n B
- I
hexane I
, O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
, O
toluene B
and O
n B
- I
butylbenzene I
. O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
involve O
stimulation O
of O
the O
soluble O
guanylate B
cyclase O
- O
cGMP B
pathway O
. O

1 B
- I
Nitro I
- I
2 I
- I
phenylethane I
is O
the O
first O
organic O
NO B
2 I
- O
containing O
molecule O
isolated O
from O
plants O
. O

The O
underlying O
mechanism O
involved O
in O
the O
vasodilator O
effect O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
was O
investigated O
in O
rat O
aorta O
. O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
did O
not O
depend O
on O
endothelial O
layer O
integrity O
, O
and O
the O
effects O
were O
refractory O
to O
L B
- I
N I
( I
G I
) I
- I
nitroarginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
- O
induced O
nitric B
oxide I
synthase O
inhibition O
. O

Conversely O
, O
methylene B
blue I
- O
and O
ODQ B
- O
induced O
guanylate B
cyclase O
inhibition O
reduced O
the O
vasorelaxation O
induced O
by O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
. O

The O
pharmacological O
blockade O
of O
K B
( I
+ I
) I
channels O
with O
tetraethylammonium B
, O
glybenclamide B
, O
and O
4 B
- I
aminopyridine I
also O
blunted O
vasorelaxation O
induced O
by O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
. O

The O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
were O
reversed O
by O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
and O
comparable O
to O
the O
effects O
induced O
by O
sodium B
nitroprusside I
. O

In O
silico O
analysis O
using O
an O
Ns O
H O
- O
NOX O
subunit O
of O
guanylate B
cyclase O
revealed O
a O
pocket O
on O
the O
macromolecule O
surface O
where O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
preferentially O
docked O
. O

In O
vitro O
, O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
increased O
cyclic B
guanosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cGMP B
) O
levels O
in O
rat O
aortic O
rings O
, O
an O
effect O
also O
reversed O
by O
ODQ B
. O

In O
conclusion O
, O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
produces O
vasodilator O
effects O
by O
stimulating O
the O
soluble O
guanylate B
cyclase O
- O
cGMP B
pathway O
. O

Alkyl B
substituted I
2 I
' I
- I
benzoylpyridine I
thiosemicarbazone I
chelators O
with O
potent O
and O
selective O
anti O
- O
neoplastic O
activity O
: O
novel O
ligands O
that O
limit O
methemoglobin O
formation O
. O

Pretreatment O
with O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
, O
previously O
shown O
to O
increase O
PLD1 O
expression O
and O
activity O
, O
had O
no O
effect O
on O
, O
and O
a O
PLD2 O
- O
selective O
( O
but O
not O
a O
PLD1 O
- O
selective O
) O
inhibitor O
decreased O
, O
cell O
lifting O
- O
induced O
PLD O
activation O
, O
suggesting O
PLD2 O
as O
the O
isoform O
activated O
. O

Stereoselective O
Rh2 B
( I
S I
- I
IBAZ I
) I
4 I
- O
catalyzed O
cyclopropanation O
of O
alkenes B
, O
alkynes B
, O
and O
allenes B
: O
asymmetric O
synthesis O
of O
diacceptor O
cyclopropylphosphona B
and O
alkylidenecyclopropa B
. O

Discovery O
of O
thiazolidine B
- I
2 I
, I
4 I
- I
dione I
/ O
biphenylcarbonitrile B
hybrid O
as O
dual O
PPAR O
alpha O
/ O
gamma O
modulator O
with O
antidiabetic O
effect O
: O
in O
vitro O
, O
in O
silico O
and O
in O
vivo O
approaches O
. O

A O
small O
series O
of O
thiazolidine B
- I
2 I
, I
4 I
- I
dione I
and O
barbituric B
acid I
derivatives O
1 O
- O
4 O
was O
prepared O
using O
a O
short O
synthetic O
route O
, O
and O
all O
compounds O
were O
characterized O
by O
elemental O
analysis O
, O
mass O
spectrometry O
, O
and O
NMR O
( O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
) O
spectroscopy O
. O

In O
this O
context O
, O
volumetric O
and O
osmotic O
coefficient O
measurements O
for O
aqueous O
solutions O
containing O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
( O
[ O
Emim B
] O
) O
based O
amino B
acid I
ionic O
liquids O
of O
glycine B
, O
alanine B
, O
valine B
, O
leucine B
, O
and O
isoleucine B
are O
reported O
at O
298 O
. O
15 O
K O
. O

nAChR O
- O
rich O
membranes O
were O
photolabeled O
with O
[ B
( I
3 I
) I
H I
] I
AziPm I
, O
and O
labeled O
amino B
acids I
were O
identified O
by O
Edman O
degradation O
. O

[ B
( I
3 I
) I
H I
] I
AziPm I
binds O
at O
three O
sites O
within O
the O
nAChR O
transmembrane O
domain O
: O
( O
i O
) O
an O
intrasubunit O
site O
in O
the O
delta O
subunit O
helix O
bundle O
, O
photolabeling O
in O
the O
nAChR O
desensitized O
state O
( O
+ O
agonist O
) O
delta O
M2 O
- O
18 O
' O
and O
two O
residues O
in O
delta O
M1 O
( O
delta B
Phe I
- O
232 O
and O
delta B
Cys I
- O
236 O
) O
; O
( O
ii O
) O
in O
the O
ion O
channel O
, O
photolabeling O
in O
the O
nAChR O
resting O
, O
closed O
channel O
state O
( O
- O
agonist O
) O
amino B
acids I
in O
the O
M2 O

Propofol B
enhanced O
[ B
( I
3 I
) I
H I
] I
AziPm I
photolabeling O
at O
alpha O
M2 O
- O
10 O
' O
. O

Propofol B
inhibited O
[ B
( I
3 I
) I
H I
] I
AziPm I
photolabeling O
within O
the O
delta O
subunit O
helix O
bundle O
at O
lower O
concentrations O
( O
IC50 O
= O
40 O
mu O
m O
) O
than O
it O
inhibited O
ion O
channel O
photolabeling O
( O
IC50 O
= O
125 O
mu O
m O
) O
. O

2 B
- I
Aminopyridin I
- I
3 I
- I
ol I
( O
1 O
) O
was O
reacted O
with O
thiophosphoryl B
chloride I
( O
2 O
) O
to O
give O
a O
monochloride B
( O
3 O
) O
. O

The O
drugs O
clinically O
used O
for O
the O
treatment O
of O
this O
disease O
, O
such O
as O
acetylcholinesterase O
inhibitors O
( O
AChEIs O
) O
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonist O
, O
can O
only O
provide O
a O
limited O
therapeutic O
effect O
. O

We O
previously O
reported O
that O
caffeoyl B
- I
amino I
acidyl I
- I
hydroxamic I
acid I
( O
CA B
- I
Xaa I
- I
NHOH I
) O
acted O
as O
both O
a O
good O
antioxidant O
and O
tyrosinase O
inhibitor O
, O
in O
particular O
when O
caffeic B
acid I
was O
conjugated O
with O
proline B
or O
amino B
acids I
having O
aromatic O
ring O
like O
phenylalanine B
. O

) I
- I
beta I
- I
d I
- I
glucoside I
, O
3 B
- I
hydroxy I
phloretin I
6 I
- I
O I
- I
hexoside I
, O
luteolin B
- I
6 I
- I
C I
- I
glucoside I
. O

A O
series O
of O
N B
- I
methylthio I
- I
beta I
- I
lactams I
with O
antibacterial O
activity O
were O
thoroughly O
evaluated O
as O
antioxidants O
. O

L B
- I
3 I
, I
4 I
- I
Dihydroxyphenylalani I
( O
L B
- I
DOPA I
) O
remains O
the O
most O
effective O
symptomatic O
treatment O
of O
Parkinson O
' O
s O
disease O
( O
PD O
) O
. O

The O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
polymer O
was O
well O
- O
characterized O
and O
studied O
in O
terms O
of O
its O
gene O
delivery O
properties O
in O
FR O
- O
positive O
KB O
cells O
and O
FR O
- O
negative O
A549 O
cells O
under O
various O
conditions O
, O
in O
comparison O
with O
cationic O
polymers O
such O
as O
high O
molecular O
weight O
branched O
polyethylenimine B
( O
PEI B
) O
, O
gamma B
- I
CD I
- I
OEI I
star O
- O
shaped O
cationic O
polymer O
, O
gamma B
- I
CD I
- I
OEI I
- I
FA I
polymer O
where O
FA O
was O
directed O
linked O
to O
the O
star O
polymer O
without O
disulfide B
linker O
. O

A O
new O
C B
( I
18 I
) I
- I
diterpenoid I
alkaloid I
, O
kirinenine B
A I
( O
1 O
) O
, O
was O
isolated O
from O
the O
root O
of O
Aconitum O
kirinense O
, O
along O
with O
eight O
known O
diterpenoid B
alkaloids I
. O

Liquified O
capsules O
featuring O
( O
i O
) O
an O
external O
shell O
by O
layer O
- O
by O
- O
layer O
assembly O
of O
poly B
( I
l I
- I
lysine I
) I
, O
alginate O
, O
and O
chitosan O
, O
and O
encapsulating O
( O
ii O
) O
surface O
functionalized O
poly B
( I
l I
- I
lactic I
acid I
) I
( O
PLLA B
) O
microparticles O
were O
developed O
. O

We O
reported O
previously O
that O
Ca B
( I
2 I
+ I
) I
influx O
through O
N B
- I
methly I
- I
d I
- I
aspartate I
- O
gated O
channels O
evokes O
ATP B
- O
sensitive O
K B
( I
+ I
) I
( O
K B
- O
ATP B
) O
currents O
in O
rat O
subthalamic O
nucleus O
( O
STN O
) O
neurons O
. O

Here O
, O
we O
found O
that O
expression O
of O
the O
PLP1 O
- O
A243V O
mutant O
, O
which O
causes O
severe O
disease O
, O
depletes O
some O
ER O
chaperones O
with O
a O
KDEL O
( O
Lys B
- I
Asp I
- I
Glu I
- I
Leu I
) O
motif O
, O
in O
HeLa O
cells O
, O
MO3 O
. O
13 O
oligodendrocytic O
cells O
, O
and O
primary O
oligodendrocytes O
. O

BChE O
was O
inhibited O
with O
Sp B
- I
and I
Rp I
- I
tabun I
thiocholine I
nerve O
agent O
model O
compounds O
to O
make O
adducts O
identical O
to O
those O
of O
tabun B
with O
known O
stereochemistry O
. O

5 B
- I
Iodo I
- I
2 I
- I
aminoindan I
( O
5 B
- I
IAI I
) O
: O
chemistry O
, O
pharmacology O
, O
and O
toxicology O
of O
a O
research O
chemical O
producing O
MDMA B
- O
like O
effects O
. O

In O
2010 O
, O
an O
internet O
snapshot O
of O
EMCDDA O
anticipated O
the O
presence O
of O
5 B
- I
iodo I
- I
2 I
- I
aminoindan I
( O
5 B
- I
IAI I
) O
within O
the O
recreational O
drug O
market O
. O

Development O
of O
amino B
- I
pyrimidine I
inhibitors O
of O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
: O
kinase O
profiling O
guided O
optimization O
of O
a O
1 B
, I
2 I
, I
3 I
- I
benzotriazole I
lead O
. O

Kinase O
profiling O
and O
structure O
- O
based O
drug O
design O
guided O
the O
optimization O
from O
the O
initial O
1 B
, I
2 I
, I
3 I
- I
benzotriazole I
hit O
to O
a O
potent O
and O
selective O
JNK O
inhibitor O
, O
compound O
24f O
( O
JNK1 O
and O
2 O
IC O
( O
50 O
) O
= O
16 O
and O
66 O
nM O
, O
respectively O
) O
, O
with O
bioavailability O
in O
rats O
and O
suitable O
for O
further O
in O
vivo O
pharmacological O
evaluation O
. O

Two O
new O
isoprenylated B
chromone I
derivatives O
, O
pestaloficiols B
Q I
( I
1 I
) I
and I
R I
( O
2 O
) O
, O
and O
one O
new O
benzofuran B
derivative O
, O
pestaloficiol B
S I
( O
3 O
) O
, O
along O
with O
three O
known O
metabolites O
, O
anofinic B
acid I
( O
4 O
) O
, O
siccayne B
( O
5 O
) O
, O
and O
pyrenophorol B
( O
6 O
) O
were O
isolated O
from O
solid O
cultures O
of O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

To O
find O
potent O
compounds O
with O
good O
pharmacokinetics O
, O
we O
used O
the O
bioisosterism O
approach O
, O
and O
designed O
the O
compound O
2 O
and O
3 O
bearing O
an O
1 B
, I
2 I
, I
4 I
- I
oxadiazole I
ring O
to O
replace O
the O
amide B
group O
in O
compound O
1 O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

Several O
new O
series O
of O
5 B
, I
6 I
, I
7 I
- I
trimethoxyindole I
derivatives O
were O
synthesized O
and O
their O
structure O
- O
activity O
relationships O
( O
SARs O
) O
were O
studied O
. O

There O
are O
many O
human O
extra O
- O
renal O
tissues O
and O
cells O
that O
biosynthesize O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
by O
the O
action O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

C34 O
- O
epi O
and O
C34 B
- I
epi I
- I
C35 I
- I
trifluoro I
analogues O
of O
solamin B
, O
a O
mono B
- I
THF I
annonaceous O
acetogenin B
, O
were O
synthesized O
. O

N B
- I
methyl I
- I
d I
- I
aspartate I
receptors O
( O
NMDARs O
) O
are O
ligand O
- O
gated O
ion O
channels O
( O
' O
ionotropic O
' O
receptors O
) O
activated O
by O
the O
major O
excitatory O
neurotransmitter O
, O
l B
- I
glutamate I
. O

Of O
the O
water O
- O
tolerant O
Lewis B
acid I
catalysts O
studied O
, O
In B
( I
OTf I
) I
( I
3 I
) I
offered O
the O
best O
phenol B
yield O
. O

Introducing O
In B
( I
OTf I
) I
( I
3 I
) I
catalysis O
lowered O
the O
activation O
energy O
for O
anisole B
hydrolysis O
to O
31 O
+ O
/ O
- O
1 O
kcal O
mol O
( O
- O
1 O
) O
. O

Anisole B
hydrolysis O
in O
high O
- O
temperature O
water O
with O
In B
( I
OTf I
) I
( I
3 I
) I
catalysis O
is O
competitive O
with O
other O
techniques O
in O
the O
literature O
based O
on O
rate O
and O
yield O
. O

In O
the O
presence O
of O
5 O
mol O
% O
In B
( I
OTf I
) I
( I
3 I
) I
catalyst O
, O
anisole B
hydrolyzes O
to O
phenol B
in O
97 O
% O
yield O
after O
90 O
minutes O
at O
300 O
degrees O
C O
. O

SDO O
variants O
M103L O
, O
G106A O
, O
G111A O
, O
R113G O
, O
S147R O
and O
F159Y O
were O
constructed O
and O
it O
was O
found O
that O
G106A O
oxidized O
only O
gentisate B
; O
1 B
- I
hydroxy I
- I
2 I
- I
naphthoate I
and O
salicylate B
were O
not O
converted O
. O

New O
pyrazole B
derivatives O
containing O
1 B
, I
2 I
, I
4 I
- I
triazoles I
and O
benzoxazoles B
as O
potent O
antimicrobial O
and O
analgesic O
agents O
. O

Present O
paper O
describes O
about O
the O
synthesis O
of O
three O
series O
of O
new O
1 B
, I
2 I
, I
4 I
- I
triazole I
and O
benzoxazole B
derivatives O
containing O
substituted O
pyrazole B
moiety O
( O
11a O
- O
d O
, O
12a O
- O
d O
and O
13a O
- O
d O
) O
. O

We O
show O
that O
Cys31 B
initiates O
the O
reaction O
with O
sulfite B
through O
the O
formation O
of O
S B
- I
sulfocysteine I
( O
RS B
- I
SO3 I
( I
2 I
- I
) I
) O
and O
Cys60 B
is O
required O
to O
fully O
derivatize O
CstR O
to O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
. O

Time O
- O
of O
- O
flight O
secondary O
ion O
mass O
spectrometry O
( O
TOF O
- O
SIMS O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
are O
employed O
to O
characterize O
a O
wedge O
- O
shaped O
crater O
eroded O
by O
a O
40 O
keV O
C B
( I
60 I
) I
( I
+ I
) I
cluster O
ion O
beam O
on O
an O
organic O
thin O
film O
of O
402 O
nm O
of O
barium B
arachidate I
( O
AA O
) O
multilayers O
prepared O
by O
the O
Langmuir O
- O
Blodgett O
( O
LB O
) O
technique O
. O

Interestingly O
and O
in O
contrast O
to O
previously O
described O
findings O
, O
( B
S I
) I
- I
6 I
- I
guanidinopurine I
derivatives O
were O
generally O
more O
active O
than O
their O
( O
R O
) O
- O
counterparts O
. O

The O
authors O
conducted O
an O
aquatic O
mesocosm O
experiment O
to O
assess O
the O
behavior O
of O
three O
NBFRs O
: O
bis B
( I
tribromophenoxy I
) I
ethane I
( O
BTBPE B
) O
, O
tetrabromobisphenol B
A I
bis I
( I
2 I
, I
3 I
- I
dibromopropyl I
ether I
; O
TBBPA B
- O
DBPE B
) O
, O
and O
Firemaster B
BZ I
- I
54 I
, O
a O
commercial O
mixture O
containing O
bis B
( I
2 I
- I
ethylhexyl I
) I
tetrabromophthalate I
( O
BEHTBP B
) O
and O
2 B
- I
ethylhexyl I
- I
2 I
, I
3 I
, I
4 I

Research O
has O
shown O
that O
the O
nitroso B
intermediates O
of O
BTZs B
that O
are O
generated O
in O
vivo O
cause O
suicide O
inhibition O
of O
decaprenylphosphoryl B
- I
beta I
- I
D I
- I
ribose I
2 O
' O
oxidase O
( O
DprE1 O
) O
, O
which O
is O
responsible O
for O
cell O
wall O
arabinogalactan O
biosynthesis O
. O

Here O
, O
a O
K B
- I
O I
( I
2 I
) I
battery O
is O
report O
that O
uses O
K B
( I
+ I
) I
ions O
to O
capture O
O B
( I
2 I
) I
( I
- I
) I
to O
form O
the O
thermodynamically O
stable O
KO B
( I
2 I
) I
product O
. O

This O
allows O
for O
the O
battery O
to O
operate O
through O
the O
one O
- O
electron O
redox O
process O
of O
O B
( I
2 I
) I
/ O
O B
( I
2 I
) I
( I
- I
) I
. O

Effects O
of O
SSR125543 B
were O
compared O
to O
those O
of O
the O
5 B
- I
HT I
reuptake O
inhibitor O
, O
paroxetine B
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
and O
the O
partial O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
agonist O
, O
D B
- I
cycloserine I
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
two O
compounds O
which O
have O
demonstrated O
clinical O
efficacy O
against O
PTSD O
. O

Samples O
were O
then O
analysed O
in O
SRM O
mode O
to O
detect O
nicotinic B
acid I
and O
nicotinic B
acid I
- I
d I
( I
4 I
) I
at O
m O
/ O
z O
124 O
- O
- O
> O
80 O
and O
127 O
- O
- O
> O
84 O
, O
respectively O
. O

Characterization O
of O
3 B
, I
4 I
- I
DHPEA I
- I
EDA I
oxidation O
products O
in O
virgin O
olive O
oil O
by O
high O
performance O
liquid O
chromatography O
coupled O
with O
mass O
spectrometry O
. O

The O
aim O
of O
this O
research O
was O
to O
characterise O
the O
dialdehydic B
form O
of O
decarboxymethyl B
elenolic I
acid I
linked O
to O
hydroxytyrosol B
( O
3 B
, I
4 I
- I
DHPEA I
- I
EDA I
) O
oxidation O
products O
to O
find O
analytical O
indicators O
that O
could O
be O
used O
as O
early O
evaluation O
index O
of O
the O
VOO O
autoxidation O
state O
. O

3 B
, I
4 I
- I
DHPEA I
- I
EDA I
was O
oxidised O
by O
enzymatic O
and O
Fenton O
reactions O
. O

Vitexin B
- I
2 I
- I
O I
- I
xyloside I
, O
raphasatin B
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
synergistically O
affect O
cell O
growth O
and O
apoptosis O
of O
colon O
cancer O
cells O
. O

Cytotoxic O
effects O
of O
the O
combination O
of O
the O
food O
components O
vitexin B
- I
2 I
- I
O I
- I
xyloside I
( O
X O
) O
, O
raphasatin B
( O
4 B
- I
methylsulphanyl I
- I
3 I
- I
butenyl I
isothiocyanates I
; O
G O
) O
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
( O
E O
) O
were O
investigated O
in O
colon O
( O
LoVo O
and O
CaCo O
- O
2 O
) O
and O
breast O
( O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
) O
cancer O
cells O
. O

NITS O
spectra O
is O
able O
to O
accurately O
predict O
for O
oleic B
, I
linoleic I
, I
and I
palmitic I
acids I
( O
R O
( O
cv O
) O
> O
0 O
. O
844 O
, O
R O
( O
2 O
) O
> O
0 O
. O
886 O
) O
. O

R O
( O
cv O
) O
are O
0 O
. O
91987 O
, O
0 O
. O
95755 O
, O
and O
0 O
. O
84447 O
, O
and O
R O
( O
2 O
) O
are O
0 O
. O
9424 O
, O
0 O
. O
9682 O
, O
0 O
. O
8862 O
for O
NITS O
models O
of O
oleic B
, I
linoleic I
, I
and I
palmitic I
acids I
, O
respectively O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

syn B
- I
ClC I
( I
O I
) I
SCN I
is O
preferred O
by O
Delta O
H O
degrees O
( O
anti O
/ O
syn O
) O
= O
1 O
. O
3 O
( O
0 O
. O
3 O
) O
kcal O
mol O
( O
- O
1 O
) O
. O

Hollow O
Multilayer O
Microcapsules O
for O
pH O
- O
/ O
Thermally O
Responsive O
Drug O
Delivery O
using O
Aliphatic B
Poly I
( I
urethane I
- I
amine I
) I
as O
Smart O
Component O
. O

Hollow O
multilayer O
microcapsules O
made O
of O
aliphatic B
poly I
( I
urethane I
- I
amine I
) I
( O
PUA B
) O
and O
sodium B
poly I
( I
styrene I
sulfonate I
) I
( O
PSS B
) O
, O
templated O
on O
PSS B
- O
doped O
CaCO3 B
particles O
, O
are O
prepared O
for O
pH O
- O
/ O
thermally O
responsive O
drug O
delivery O
. O

Well O
- O
defined O
amphiphilic O
linear O
- O
dendritic O
prodrugs O
( O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
) O
are O
synthesized O
by O
conjugating O
doxorubicin B
( O
DOX B
) O
, O
to O
MPEG B
- I
b I
- I
PAMAM I
through O
the O
acid O
- O
labile O
hydrazone B
bond O
. O

In O
vitro O
methyl B
thiazolyl I
tetrazolium I
( O
MTT B
) O
assays O
and O
drug O
- O
induced O
apoptosis O
tests O
demonstrate O
the O
HCPT B
- O
loaded O
nanoparticles O
suppress O
cancer O
cell O
growth O
more O
efficiently O
than O
the O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
prodrugs O
, O
free O
HCPT B
, O
and O
physical O
mixtures O
of O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
and O
HCPT B
at O
equivalent O
DOX B
or O
HCPT B
doses O
. O

In O
vitro O
methyl B
thiazolyl I
tetrazolium I
( O
MTT B
) O
assays O
and O
drug O
- O
induced O
apoptosis O
tests O
demonstrate O
the O
HCPT B
- O
loaded O
nanoparticles O
suppress O
cancer O
cell O
growth O
more O
efficiently O
than O
the O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
prodrugs O
, O
free O
HCPT B
, O
and O
physical O
mixtures O
of O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
and O
HCPT B
at O
equivalent O
DOX B
or O
HCPT B
doses O
. O

The O
molecular O
orientation O
and O
dynamics O
of O
di B
- I
t I
- I
butylnitroxide I
( O
DTBN B
) O
and O
4 B
- I
oxo I
- I
2 I
, I
2 I
, I
6 I
, I
6 I
- I
tetramethyl I
- I
1 I
- I
piperidinyl I
- I
1 I
- I
oxyl I
( O
TEMPONE B
) O
radicals O
in O
the O
organic O
1D O
nanochannels O
of O
tris B
( I
o I
- I
phenylenedioxy I
) I
cyclotriphosphazene I
( O
TPP B
) O
were O
investigated O
by O
examining O
inclusion O
compounds O
( O
ICs O
) O
diluted O
by O
the O
co O
- O
inclusion O
of O
nonradicals O
using O
electron O
spin O
resonance O
( O

Metabolic O
dephenylation O
of O
the O
rubber O
antioxidant O
N B
- I
phenyl I
- I
2 I
- I
naphthylamine I
to O
carcinogenic O
2 B
- I
naphthylamine I
in O
rats O
. O

N B
- I
Phenyl I
- I
2 I
- I
naphthylamine I
( O
P2NA B
) O
was O
widely O
used O
as O
oxidation O
inhibitor O
, O
particularly O
in O
rubber O
manufacturing O
. O

Accurate O
semiexperimental O
structure O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
by O
the O
mixed O
estimation O
method O
. O

In O
order O
to O
determine O
an O
accurate O
equilibrium O
structure O
for O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
, O
microwave O
transitions O
and O
ground O
- O
state O
rotational O
constants O
are O
reported O
for O
the O
parent O
species O
and O
for O
the O
( B
18 I
) I
O I
isotopologue O
measured O
in O
natural O
abundance O
. O

Catalase O
, O
glutathione B
- O
S B
- O
transferase O
and O
xanthine B
oxidase O
activities O
were O
not O
altered O
by O
atorvastatin B
treatment O
or O
withdrawal O
, O
as O
well O
as O
protein O
carbonyl B
and O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
immunoreactivity O
. O

N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
( O
NMDARs O
) O
and O
nicotinic O
acetylcholine B
receptors O
( O
nACHRs O
) O
are O
thought O
to O
be O
effective O
in O
the O
learning O
and O
memory O
- O
generating O
process O
. O

MDA O
- O
MB O
- O
231 O
/ O
ADM O
contained O
fewer O
methylated O
CpG B
sites O
than O
its O
parental O
cell O
line O
, O
and O
miR O
- O
663 O
expression O
in O
MDA O
- O
MB O
- O
231 O
cells O
was O
reactivated O
by O
5 B
- I
aza I
- I
29 I
- I
deoxycytidine I
treatment O
, O
indicating O
that O
DNA O
methylation O
may O
play O
a O
functional O
role O
in O
the O
expression O
of O
miR O
- O
663 O
. O

In O
this O
study O
, O
six O
healthy O
adult O
male O
subjects O
received O
a O
single O
i O
. O
v O
. O
dose O
of O
[ B
( I
14 I
) I
C I
] I
GSK2251052 I
, O
1500 O
mg O
infused O
over O
1 O
hour O
. O

The O
convergent O
synthetic O
strategy O
includes O
the O
preparation O
of O
a O
trans B
- I
A2 I
B I
- I
corrole I
possessing O
the O
imide B
unit O
, O
followed O
by O
Sonogashira O
coupling O
with O
a O
meso B
- I
substituted I
A3 I
B I
- I
porphyrin I
. O

The O
treatment O
of O
mice O
with O
Fe B
- I
NTA I
alone O
enhances O
ornithine B
decarboxylase O
activity O
to O
4 O
. O
6 O
folds O
, O
protein O
carbonyl B
formation O
increased O
up O
to O
2 O
. O
9 O
folds O
and O
DNA O
synthesis O
expressed O
in O
terms O
of O
[ B
( I
3 I
) I
H I
] I
thymidine I
incorporation O
increased O
to O
3 O
. O
2 O
folds O
, O
and O
antioxidants O
and O
antioxidant O
enzymes O
decreased O
to O
1 O
. O
8 O
- O
2 O
. O
5 O
folds O
, O
compared O
with O
the O
corresponding O
saline O
- O
treated O
controls O
. O

For O
the O
current O
study O
the O
pigment O
- O
protein O
complexes O
were O
stabilized O
in O
the O
detergent O
buffer O
solution O
using O
a O
relatively O
mild O
detergent O
( O
dodecyl B
- I
beta I
- I
D I
- I
maltoside I
( O
DDM B
) O
instead O
of O
lauryldimethylamine B
N I
- I
oxide I
( O
LDAO B
) O
) O
. O

The O
Si B
- I
H I
surface O
can O
then O
be O
modified O
by O
thermal O
hydrosilylation O
( O
1 B
- I
dodecene I
or O
10 B
- I
bromo I
- I
1 I
- I
decene I
) O
in O
a O
subsequent O
step O
, O
resulting O
in O
a O
bifunctional O
porous O
Si B
film O
containing O
hydrophobic O
pore O
entrances O
to O
hydrophilic O
inner O
pores O
. O

Here O
, O
we O
investigated O
the O
role O
of O
NPS O
in O
memory O
formation O
, O
and O
determined O
whether O
NPS O
could O
mitigate O
memory O
impairment O
induced O
by O
selective O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptor O
antagonist O
MK801 B
, O
muscarinic O
cholinergic O
receptor O
antagonist O
scopolamine B
or O
A O
beta O
1 O
- O
42 O
in O
mice O
, O
using O
novel O
object O
and O
object O
location O
recognition O
tasks O
. O

To O
evaluate O
this O
approach O
, O
the O
behavior O
of O
2 B
- I
methoxy I
- I
4 I
- I
methylphenol I
( O
2M4MP B
) O
, O
reported O
as O
a O
moderate O
sensitizer O
according O
to O
the O
Local O
Lymph O
Node O
Assay O
( O
LLNA O
) O
, O
has O
been O
investigated O
in O
this O
assay O
. O

Three O
free O
unusual O
amino B
acids I
, O
named O
N B
- I
methyl I
- I
alpha I
- I
alanine I
, O
N B
- I
methyl I
- I
beta I
- I
alanine I
, O
and O
2 B
, I
7 I
- I
diaminooctan I
- I
1 I
, I
8 I
- I
dioic I
acid I
, O
described O
for O
the O
first O
time O
in O
a O
plant O
, O
and O
known O
trigonelline B
were O
also O
isolated O
from O
the O
stem O
bark O
of O
D O
. O
michelsonii O
. O

Three O
free O
unusual O
amino B
acids I
, O
named O
N B
- I
methyl I
- I
alpha I
- I
alanine I
, O
N B
- I
methyl I
- I
beta I
- I
alanine I
, O
and O
2 B
, I
7 I
- I
diaminooctan I
- I
1 I
, I
8 I
- I
dioic I
acid I
, O
described O
for O
the O
first O
time O
in O
a O
plant O
, O
and O
known O
trigonelline B
were O
also O
isolated O
from O
the O
stem O
bark O
of O
D O
. O
michelsonii O
. O

In O
our O
study O
, O
biocompatible O
Ni B
( I
II I
) I
- I
nitrilo I
( I
triacetic I
acid I
) I
- O
modified O
poly B
( I
ethylene I
imine I
) I
- I
maltose I
( O
Ni B
- I
NTA I
- I
DG I
) O
is O
realized O
and O
evaluated O
as O
complexation O
agent O
against O
His B
- O
tagged O
peptides O
using O
fluorescence O
polarization O
and O
dynamic O
light O
scattering O
. O

PDE4 O
is O
one O
of O
eleven O
known O
cyclic B
nucleotide I
phosphodiesterase O
families O
and O
plays O
a O
pivotal O
role O
in O
mediating O
hydrolytic O
degradation O
of O
the O
important O
cyclic B
nucleotide I
second O
messenger O
, O
cyclic B
3 I
' I
5 I
' I
adenosine I
monophosphate I
( O
cAMP B
) O
. O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate B
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

Several O
1 B
- I
phenylbenzo I
[ I
c I
] I
phenanthridines I
exhibit O
notable O
antibacterial O
activity O
. O

Increasing O
pH O
, O
as O
in O
some O
aged O
food O
products O
, O
decreases O
the O
solubility O
, O
and O
Ksp O
( O
' O
) O
= O
[ O
Ca B
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
[ I
OH I
( I
- I
) I
] O
is O
found O
constant O
rather O
than O
Ksp O
= O
[ B
Ca I
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
( I
2 I
) I
in O
agreement O
with O
an O
initial O
precipitation O
of O
Ca B
( I
OH I
) I
( I
Pal I
) I
, O
which O
slowly O
may O
convert O
into O
Ca B
( I
Pal I
) I
2 I
. I
Ca I
( I
OH I
) I
( I
Pal I
) I
has O
a O
solubility O
minimum O
at O
physiological O
ionic O
strength O
with O
Ksp O
( O

The O
commonly O
- O
used O
chromogenic O
substrate O
gamma B
- I
glutamyl I
- I
p I
- I
nitroanilide I
was O
also O
tested O
. O

The O
aim O
was O
to O
assess O
the O
impact O
on O
biological O
activities O
of O
the O
replacement O
of O
the O
1 B
, I
2 I
, I
4 I
- I
thiadiazine I
ring O
by O
an O
isosteric O
1 B
, I
4 I
, I
2 I
- I
dithiazine I
ring O
. O

The O
aim O
was O
to O
assess O
the O
impact O
on O
biological O
activities O
of O
the O
replacement O
of O
the O
1 B
, I
2 I
, I
4 I
- I
thiadiazine I
ring O
by O
an O
isosteric O
1 B
, I
4 I
, I
2 I
- I
dithiazine I
ring O
. O

These O
results O
cannot O
be O
explained O
by O
a O
direct O
interaction O
of O
sigma O
1 O
ligands O
with O
mu O
- O
opioid O
receptors O
or O
adaptive O
changes O
of O
mu O
- O
receptors O
in O
sigma O
1 O
- O
KO O
mice O
, O
given O
that O
[ B
( I
3 I
) I
H I
] I
DAMGO I
binding O
in O
forebrain O
, O
spinal O
cord O
, O
and O
hind O
- O
paw O
skin O
membranes O
was O
unaltered O
in O
mutant O
mice O
, O
and O
none O
of O
the O
sigma O
1 O
drugs O
tested O
bound O
to O
mu O
- O
opioid O
receptors O
. O

Enhanced O
broadband O
and O
omnidirectional O
performance O
of O
Cu B
( I
In I
, I
Ga I
) I
Se2 I
solar O
cells O
with O
ZnO B
functional O
nanotree O
arrays O
. O

An O
effective O
approach O
is O
demonstrated O
for O
enhancing O
photoelectric O
conversion O
of O
Cu B
( I
In I
, I
Ga I
) I
Se2 I
( O
CIGS B
) O
solar O
cells O
with O
three O
- O
dimensional O
ZnO B
nanotree O
arrays O
. O

Psychoactive O
compounds O
, O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
( O
NMDAR O
) O
antagonists O
, O
modify O
gamma O
( O
40 O
- O
90 O
) O
and O
high O
frequency O
oscillations O
( O
HFO O
, O
130 O
- O
180 O
Hz O
) O
in O
local O
field O
potentials O
( O
LFPs O
) O
recorded O
in O
the O
NAc O
. O

To O
demonstrate O
the O
use O
of O
this O
technique O
for O
investigating O
potential O
endocrine O
disrupting O
effects O
, O
zebrafish O
embryos O
were O
exposed O
to O
1 O
, O
10 O
and O
100nM O
6 B
- I
OH I
- I
BDE I
- I
47 I
. O

In O
aqueous O
suspensions O
at O
pH O
10 O
corrected O
Debye O
- O
H O
u O
ckel O
theory O
for O
surface O
complexation O
calculations O
predict O
that O
smaller O
silica B
colloids O
have O
increased O
negative O
surface O
charge O
density O
that O
originates O
from O
enhanced O
screening O
of O
deprotonated O
silanol B
groups O
( O
= B
Si I
- I
O I
( I
- I
) I
) O
by O
counterions O
in O
the O
condensed O
ion O
layer O
. O

Addition O
of O
10 O
mu O
M O
of O
progesterone B
, O
5 B
alpha I
- I
dihydroprogesterone I
( O
5 B
alpha I
- I
DHP I
) O
or O
allopregnanolone B
( O
3 B
alpha I
, I
5 I
alpha I
- I
tetrahydroprogestero I
) O
to O
the O
medium O
at O
the O
time O
of O
injury O
rescued O
the O
spinal O
cord O
slices O
from O
the O
effects O
of O
damage O
. O

In O
three O
- O
dimensional O
( O
3D O
) O
cell O
cultures O
consisting O
of O
MCF O
- O
7 O
breast O
cancer O
cell O
spheroids O
that O
were O
placed O
on O
lymph O
- O
endothelial O
cell O
( O
LEC O
) O
monolayers O
, O
tumour O
cell O
spheroids O
induce O
" O
circular O
chemorepellent O
- O
induced O
defects O
" O
( O
CCIDs O
) O
in O
the O
LEC O
monolayer O
; O
12 B
( I
S I
) I
- I
Hydroxyeicosatetraen I
acid I
( O
12 B
( I
S I
) I
- I
HETE I
) O
and O
NF O
- O
kappa O
B O
activity O
are O
major O
factors O
inducing O
CCIDs O
, O
which O
are O
entry O
gates O
for O
tumour O
emboli O

In O
vitro O
intestinal O
and O
hepatic O
metabolism O
of O
Di B
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
in O
human O
and O
rat O
. O

In O
this O
proof O
- O
of O
- O
concept O
study O
, O
we O
introduced O
a O
3 B
- I
amino I
- I
4 I
- I
piperazinylphenyl I
functionality O
to O
the O
chromone B
scaffold O
and O
evaluated O
the O
antiviral O
activities O
of O
the O
resulting O
chromone B
derivatives O
. O

The O
structures O
of O
three O
aromatic O
- O
rich O
isolated O
peptides O
, O
Ac B
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FF O
) O
, O
Ac B
- I
Trp I
- I
Tyr I
- I
NH2 I
( O
WY O
) O
, O
and O
Ac B
- I
Phe I
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FFF O
) O
, O
all O
in O
the O
gas O
phase O
, O
have O
been O
studied O
by O
infrared O
- O
ultraviolet O
( O
IR O
/ O
UV O
) O
double O
resonance O
laser O
spectroscopy O
, O
aided O
by O
dispersion O
- O
corrected O
density O
functional O
theory O
( O
DFT O
- O
D O
) O
calculations O
. O

The O
structures O
of O
three O
aromatic O
- O
rich O
isolated O
peptides O
, O
Ac B
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FF O
) O
, O
Ac B
- I
Trp I
- I
Tyr I
- I
NH2 I
( O
WY O
) O
, O
and O
Ac B
- I
Phe I
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FFF O
) O
, O
all O
in O
the O
gas O
phase O
, O
have O
been O
studied O
by O
infrared O
- O
ultraviolet O
( O
IR O
/ O
UV O
) O
double O
resonance O
laser O
spectroscopy O
, O
aided O
by O
dispersion O
- O
corrected O
density O
functional O
theory O
( O
DFT O
- O
D O
) O
calculations O
. O

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

Chemical O
examination O
of O
a O
South O
China O
Sea O
soft O
coral O
Lobophytum O
sp O
. O
led O
to O
the O
isolation O
of O
three O
new O
alpha B
- I
methylene I
- I
gamma I
- I
lactone I
- O
containing O
cembranoids B
, O
( B
1R I
* I
, I
3R I
* I
, I
4R I
* I
, I
14R I
* I
, I
7E I
, I
11E I
) I
- I
3 I
, I
4 I
- I
epoxycembra I
- I
7 I
, I
11 I
, I
15 I
( I
17 I
) I
- I
trien I
- I
16 I
, I
14 I
- I
olide I
( O
1 O
) O
, O
( B
1R I
* I
, I
7S I
* I
, I
14S I
* I
, I
3E I
, I
11E I
) I
- I
7 I
- I

U B
- I
73122 I
, O
a O
phospholipase O
C O
( O
PLC O
) O
inhibitor O
, O
and O
2 B
- I
aminoethoxydiphenyl I
borate I
, O
an O
inositol B
1 I
, I
4 I
, I
5 I
trisphosphate I
( O
IP3 O
) O
receptor O
antagonist O
, O
attenuated O
hUII O
- O
induced O
MAP O
and O
RVR O
elevations O
, O
RBF O
and O
CBF O
reductions O
, O
but O
not O
MBF O
increase O
. O

Liposomes O
were O
composed O
of O
phosphatidylcholine B
, O
hydrogenated O
soy O
phosphatidylcholine B
( O
HSPC O
) O
, O
stearylamine B
, O
alpha B
- I
tocopherol I
and O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphoethanolamine I
- I
N I
- I
[ I
amino I
( I
polyethylene I
glycol I
) I
- I
2000 I
] I
( O
PEG B
- I
DSPE I
) O
or O
folate B
- I
polyethylene I
glycol I
- I
cholesteryl I
hemisuccinate I
( O
F B
- I

A O
series O
of O
sugar B
- O
modified O
derivatives O
of O
cytostatic O
7 B
- I
heteroaryl I
- I
7 I
- I
deazaadenosines I
( O
2 B
' I
- I
deoxy I
- I
2 I
' I
- I
fluororibo I
- I
and I
2 I
' I
- I
deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibonucleosi I
) O
bearing O
an O
aryl B
or O
heteroaryl B
group O
at O
position O
7 O
was O
prepared O
and O
screened O
for O
biological O
activity O
. O

The O
difluororibonucleosi B
were O
prepared O
by O
non O
- O
stereoselective O
glycosidation O
of O
6 B
- I
chloro I
- I
7 I
- I
deazapurine I
with O
benzoyl B
- I
protected I
2 I
- I
deoxy I
- I
2 I
, I
2 I
- I
difluoro I
- I
D I
- I
erythro I
- I
pentofuranosyl I
- I
1 I
- I
mesylate I
, O
followed O
by O
amination O
and O
aqueous O
Suzuki O
cross O
- O
couplings O
with O
( B
het I
) I
arylboronic I
acids I
. O

Some O
of O
the O
title O
nucleosides B
and O
7 B
- I
iodo I
- I
7 I
- I
deazaadenine I
intermediates O
showed O
micromolar O
cytostatic O
or O
anti O
- O
HCV O
activity O
. O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

Cyanidin B
- I
3 I
- I
O I
- I
glucoside I
was O
considered O
as O
the O
most O
abundant O
anthocyanin B
, O
which O
was O
29 O
. O
4mg O
/ O
100g O
dry O
weight O
of O
R O
. O
tomentosa O
fruits O
. O

Six O
new O
sesquiterpenoids B
, O
aristoyunnolins B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
an O
artifact O
of O
isolation O
[ O
7 B
- I
O I
- I
ethyl I
madolin I
W I
( O
7 O
) O
] O
, O
and O
12 O
known O
analogues O
were O
isolated O
from O
stems O
of O
Aristolochia O
yunnanensis O
. O

After O
each O
period O
, O
subjects O
received O
a O
6 O
- O
h O
meal O
tolerance O
test O
( O
MTT B
) O
with O
[ B
( I
14 I
) I
C I
] I
glucose I
to O
calculate O
glucose B
kinetics O
. O

Quantitative O
autoradiography O
was O
used O
to O
measure O
cytisine B
- O
sensitive O
[ B
( I
125 I
) I
I I
] I
epibatidine I
and O
[ O
( B
125 I
) I
I I
] O
alpha O
- O
bungarotoxin O
binding O
to O
alpha O
4 O
beta O
2 O
* O
and O
alpha O
7 O
nAChRs O
, O
respectively O
, O
in O
brain O
sections O
of O
drug O
- O
na O
i O
ve O
( O
n O
= O
6 O
) O
or O
nicotine B
treated O
( O
n O
= O
5 O
- O
7 O
) O
, O
wild O
- O
type O
and O
adenosine B
A2AR O
knockout O
mice O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

When O
the O
temperature O
is O
below O
1000 O
K O
, O
the O
reaction O
R15 O
forming O
the O
cyclic B
ether I
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
, O
is O
dominant O
; O
while O
the O
reaction O
R13 O
forming O
acetic B
acid I
+ O
ethylene B
+ O
y O
OH B
radical O
becomes O
increasingly O
dominant O
at O
temperatures O
above O
1000 O
K O
. O

The O
other O
two O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
, O
2 B
- I
buten I
- I
2 I
- I
ol I
and O
HO2 B
radical O
are O
not O
dominant O
but O
are O
still O
important O
product O
channels O
over O
the O
whole O
temperature O
range O
investigated O
here O
. O

The O
other O
two O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
, O
2 B
- I
buten I
- I
2 I
- I
ol I
and O
HO2 B
radical O
are O
not O
dominant O
but O
are O
still O
important O
product O
channels O
over O
the O
whole O
temperature O
range O
investigated O
here O
. O

No O
pressure O
dependence O
has O
been O
found O
for O
the O
reaction O
channels O
forming O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
OH B
radical O
and O
acetic B
acid I
+ O
ethylene B
+ O
OH B
radical O
. O

Electrophysiological O
evidence O
for O
4 B
- I
isobutyl I
- I
3 I
- I
isopropylbicyclophos I
as O
a O
selective O
blocker O
of O
insect O
GABA B
- O
gated O
chloride B
channels O
. O

The O
antagonism O
of O
GABACls O
and O
GluCls O
by O
4 B
- I
isobutyl I
- I
3 I
- I
isopropylbicyclophos I
( O
PS B
- I
14 I
) O
was O
examined O
in O
cultured O
cockroach O
and O
rat O
neurons O
using O
a O
whole O
- O
cell O
patch O
- O
clamp O
method O
. O

1D O
and O
2D O
NMR O
spectroscopy O
revealed O
that O
the O
O B
- O
specific O
polysaccharide O
( O
OPS O
) O
of O
A O
. O
bestiarum O
K296 O
consists O
of O
a O
branched O
tetrasaccharide B
repeating O
unit O
containing O
two O
6 B
- I
deoxy I
- I
l I
- I
talose I
( O
6dTalp B
) O
, O
one O
Manp O
and O
one O
GalpNAc B
residues O
; O
thus O
, O
it O
is O
similar O
to O
that O
of O
the O
OPS O
of O
A O
. O
hydrophila O
AH O
- O
3 O
( O
serotype O
O34 O
) O
in O
both O
the O
sugar B
composition O
and O
the O
glycosylation O
pattern O
. O

Ionically O
cross O
- O
linked O
multilayers O
~ O
120 O
nm O
thick O
were O
fabricated O
layer O
- O
by O
- O
layer O
on O
the O
surfaces O
of O
balloon O
- O
mounted O
stainless O
steel O
stents O
using O
plasmid O
DNA O
and O
a O
hydrolytically O
degradable O
poly B
( I
beta I
- I
amino I
ester I
) I
( O
polymer O
1 O
) O
. O

By O
varying O
the O
substituents O
( O
R O
( O
1 O
) O
) O
at O
the O
indolin B
- I
2 I
- I
one I
scaffold O
, O
a O
series O
of O
indolin B
- I
2 I
- I
one I
derivatives O
bearing O
4 B
- I
phenylpiperazine I
- I
1 I
- I
carbothiohydrazide I
moiety O
at O
the O
C3 O
- O
position O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
activity O
against O
three O
human O
cancer O
cell O
lines O
. O

We O
further O
selected O
the O
5 B
- I
chloroindolin I
- I
2 I
- I
one I
moiety O
for O
the O
extension O
to O
another O
series O
of O
compounds O
by O
varying O
the O
substituents O
( O
R O
( O
2 O
) O
) O
at O
the O
phenyl B
group O
connected O
with O
the O
piperazine B
ring O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

The O
O B
- I
methyl I
free O
derivatives O
used O
in O
the O
study O
were O
fully O
trimethylated O
( O
100 O
% O
) O
N B
, I
N I
, I
N I
- I
trimethyl I
chitosan O
( O
TMC O
) O
and O
N B
- I
propyl I
- I
( I
QuatPropyl I
) I
, O
N B
- I
butyl I
- I
( I
QuatButyl I
) I
and O
N B
- I
hexyl I
( I
QuatHexyl I
) I
- I
N I
, I
N I
- I
dimethyl I
chitosan O
, O
with O
85 O
- O
91 O
% O
degree O
of O
quaternization O
. O

The O
O B
- I
methyl I
free O
derivatives O
used O
in O
the O
study O
were O
fully O
trimethylated O
( O
100 O
% O
) O
N B
, I
N I
, I
N I
- I
trimethyl I
chitosan O
( O
TMC O
) O
and O
N B
- I
propyl I
- I
( I
QuatPropyl I
) I
, O
N B
- I
butyl I
- I
( I
QuatButyl I
) I
and O
N B
- I
hexyl I
( I
QuatHexyl I
) I
- I
N I
, I
N I
- I
dimethyl I
chitosan O
, O
with O
85 O
- O
91 O
% O
degree O
of O
quaternization O
. O

The O
O B
- I
methyl I
free O
derivatives O
used O
in O
the O
study O
were O
fully O
trimethylated O
( O
100 O
% O
) O
N B
, I
N I
, I
N I
- I
trimethyl I
chitosan O
( O
TMC O
) O
and O
N B
- I
propyl I
- I
( I
QuatPropyl I
) I
, O
N B
- I
butyl I
- I
( I
QuatButyl I
) I
and O
N B
- I
hexyl I
( I
QuatHexyl I
) I
- I
N I
, I
N I
- I
dimethyl I
chitosan O
, O
with O
85 O
- O
91 O
% O
degree O
of O
quaternization O
. O

We O
describe O
common O
strategies O
for O
mass O
spectrometric O
analysis O
of O
stable O
isotope O
labeled O
samples O
, O
as O
well O
as O
two O
widely O
applied O
phosphopeptide O
enrichment O
methods O
based O
on O
IMAC O
( O
NTA B
- I
Fe I
( I
3 I
+ I
) I
) O
and O
metal B
oxide I
( O
ZrO2 B
) O
. O

Uptake O
was O
measured O
at O
multiple O
concentrations O
( O
0 O
. O
5 O
, O
3 O
, O
10 O
, O
30ppm O
) O
in O
controls O
and O
mice O
treated O
with O
the O
cytochrome O
P450 O
inhibitor O
5 B
- I
phenyl I
- I
1 I
- I
pentyne I
. O

Both O
uptake O
efficiency O
and O
the O
concentration O
dependence O
of O
uptake O
were O
significantly O
diminished O
by O
5 B
- I
phenyl I
- I
1 I
- I
pentyne I
indicating O
inspired O
naphthalene B
vapor O
is O
extensively O
metabolized O
in O
the O
mouse O
nose O
with O
saturation O
of O
metabolism O
occurring O
at O
the O
higher O
concentrations O
. O

Maternal O
exposure O
to O
di B
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
decreased O
the O
plasma O
triglyceride B
in O
prepartum O
mice O
. O

Several O
chiral O
ligands O
containing O
( B
R I
, I
R I
) I
- I
diaminocyclohexane I
moieties O
and O
pyrrole B
, O
furan B
, O
or O
benzene B
have O
been O
synthesized O
. O

These O
ligands O
were O
tested O
in O
enantioselective O
zinc B
- O
catalyzed O
hydrosilylation O
reactions O
; O
excellent O
enantioselectivities O
were O
obtained O
when O
the O
ligands O
containing O
( B
R I
, I
R I
) I
- I
diaminocyclohexane I
moieties O
and O
furan B
rings O
were O
used O
. O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

The O
most O
active O
compound O
, O
3 B
, I
3 I
- I
dibromoflavanone I
( O
31 O
) O
, O
a O
synthetic O
flavonoid B
, O
presented O
a O
significant O
inhibition O
of O
the O
binding O
of O
the O
selective O
mu O
opioid O
ligand O
[ B
( I
3 I
) I
H I
] I
DAMGO I
, O
with O
a O
Ki O
of O
0 O
. O
846 O
+ O
/ O
- O
0 O
. O
263 O
mu O
M O
. O

OBJECTIVE O
: O
The O
goal O
was O
to O
determine O
the O
role O
of O
VTA O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
( O
NMDARs O
) O
and O
specific O
subtypes O
of O
nicotinic O
acetylcholine B
receptors O
( O
nAChRs O
) O
in O
regulating O
phasic O
DA O
release O
in O
the O
NAc O
core O
. O

OBJECTIVE O
: O
To O
investigate O
the O
antioxidant O
role O
in O
reversing O
cytogenetic O
changes O
caused O
by O
solvent O
exposure O
in O
paint O
industry O
. O
Subjects O
and O
METHODS O
: O
A O
prospective O
controlled O
clinical O
trial O
was O
performed O
on O
39 O
workers O
exposed O
to O
solvents O
and O
39 O
workers O
not O
exposed O
to O
solvents O
by O
supplying O
a O
mixture O
of O
antioxidant O
vitamins B
( I
A I
, I
C I
, I
E I
and O
selenium B
) O
and O
the O
after O
effects O
of O
such O
regimen O
were O
analyzed O
. O

We O
utilized O
a O
series O
of O
N B
- I
hydroxypyrazole I
- I
5 I
- I
glycine I
( O
NHP5G B
) O
partial O
agonists O
at O
the O
GluN2 O
glutamate B
binding O
site O
as O
tools O
to O
study O
activation O
of O
GluN1 O
/ O
GluN2A O
and O
GluN1 O
/ O
GluN2D O
NMDA B
receptor O
subtypes O
. O

We O
show O
using O
two O
- O
electrode O
voltage O
- O
clamp O
electrophysiology O
, O
fast O
- O
application O
patch O
- O
clamp O
, O
and O
single O
channel O
recordings O
that O
propyl B
- I
and I
ethyl I
- I
substituted I
NHP5G I
agonists O
have O
a O
broad O
range O
of O
agonist O
efficacies O
relative O
to O
the O
full O
agonist O
glutamate B
( O
< O
1 O
% O
- O
72 O
% O
) O
. O

The O
trisulfur B
radical O
anion O
[ B
S3 I
] I
. I
( I
- I
) I
is O
well O
- O
known O
from O
inorganic O
chemistry O
textbooks O
as O
the O
blue O
chromophore O
in O
ultramarine O
blues O
in O
which O
this O
highly O
reactive O
species O
is O
trapped O
in O
a O
zeolitic O
framework O
. O

Recent O
findings O
have O
revealed O
that O
[ B
S3 I
] I
. I
( I
- I
) I
has O
a O
multi O
- O
faceted O
role O
in O
a O
variety O
of O
media O
, O
including O
alkali O
metal O
- O
sulfur B
batteries O
, O
aqueous O
solutions O
at O
high O
temperatures O
and O
pressures O
, O
and O
ionic O
liquids O
; O
it O
has O
also O
been O
used O
to O
detect O
trace O
amounts O
of O
water O
in O
organic O
solvents O
. O

Examples O
of O
the O
function O
of O
[ B
S3 I
] I
. I
( I
- I
) I
in O
materials O
science O
, O
electrochemistry O
, O
analytical O
chemistry O
and O
geochemistry O
are O
used O
to O
illustrate O
the O
widespread O
influence O
of O
this O
fundamentally O
important O
triatomic B
sulfur I
species O
. O

This O
extract O
afforded O
six O
new O
isoflavonoids B
, O
sedonans B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
a O
new O
but B
- I
2 I
- I
enolide I
, O
4 B
' I
- I
O I
- I
methylpuerol I
A I
( O
7 O
) O
, O
and O
the O
new O
pterocarpan O
ent B
- I
sandwicensin I
( O
8 O
) O
. O

Their O
structures O
were O
characterised O
as O
16 B
- I
deethylindanomycin I
( O
2 O
) O
, O
iso B
- I
16 I
- I
deethylindanomycin I
( O
3 O
) O
, O
16 B
- I
deethylindanomycin I
methyl I
ester I
( O
4 O
) O
and O
iso B
- I
16 I
- I
deethylindanomycin I
methyl I
ester I
( O
5 O
) O
on O
the O
basis O
of O
NMR O
, O
HR O
- O
ESI O
- O
MS O
and O
CD O
evidences O
. O

GRE O
contained O
higher O
levels O
of O
all O
compounds O
, O
except O
the O
enolic O
phenylpyruvic B
acid I
- I
2 I
- I
O I
- I
glucoside I
and O
luteolin B
- I
7 I
- I
O I
- I
glucoside I
. O

Synthesis O
of O
some O
novel O
biologically O
active O
piperidin B
- I
4 I
- I
one I
oxime I
carbonates I
from O
1 B
- I
methyl I
- I
3alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oximes I
and O
substituted O
chloroformates B
was O
carried O
out O
in O
the O
presence O
of O
potassium B
carbonate I
as O
base O
and O
tetrabutylammonium B
bromide I
( O
TBAB B
) O
as O
catalyst O
. O

While O
citronellyl B
nitrile I
, O
3 B
- I
methyl I
- I
5 I
- I
phenylpentanenitrile I
, O
cinnamyl B
nitrile I
, O
and O
3 B
- I
methyl I
- I
5 I
- I
phenylpent I
- I
2 I
- I
enenitrile I
revealed O
positive O
results O
in O
the O
in O
- O
vitro O
tests O
, O
but O
confirmatory O
in O
- O
vivo O
tests O
determined O
these O
nitriles B
to O
be O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
assay O
. O

Whole O
blood O
collagen O
- O
induced O
platelet O
aggregation O
and O
calcium B
- O
induced O
thromboxane B
B2 I
( O
TxB2 B
) O
, O
aortic O
6 B
- I
keto I
- I
prostaglandin I
F1 I
alpha I
( O
6 B
- I
keto I
- I
PGF1 I
alpha I
) O
and O
nitrites B
+ O
nitrates B
, O
plasma O
concentration O
of O
lipid O
peroxides B
( O
TBARS O
) O
and O
red O
blood O
cell O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
were O
measured O
. O

Single O
crystal O
X O
- O
ray O
diffraction O
studies O
revealed O
that O
the O
copper B
( I
I I
) I
complex O
[ B
CuCl I
( I
PPh3 I
) I
L I
] I
has O
a O
distorted O
tetrahedral O
geometry O
around O
the O
central O
copper B
( I
I I
) I
ion O
. O

4 B
- I
Aminoalkoxy I
substituents O
provided O
the O
most O
potent O
derivatives O
, O
with O
the O
4 B
- I
O I
( I
CH2 I
) I
3NMe2 I
analog O
( O
compound O
14 O
) O
being O
identified O
as O
displaying O
the O
best O
overall O
activity O
in O
combination O
with O
good O
aqueous O
solubility O
( O
25 O
mg O
/ O
mL O
for O
the O
hydrochloride B
salt O
) O
. O

Nitroimidazolyl B
hydrazones I
are O
better O
amoebicides O
than O
their O
cyclized O
1 B
, I
3 I
, I
4 I
- I
oxadiazoline I
analogues O
: O
In O
vitro O
studies O
and O
Lipophilic O
efficiency O
analysis O
. O

